Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Snowflake prices USD 3.75 billion zero-coupon convertible senior notes offering

Snowflake prices USD 3.75 billion zero-coupon convertible senior notes offering

BitgetBitget2026/09/29 06:31
  • Snowflake priced a USD 3.75 billion upsized private placement of 0.00% Convertible Senior Notes.
  • Issuance split into USD 2 billion due 2029, USD 1.75 billion due 2031.
  • Initial purchasers received 13-day options for up to USD 550 million additional notes; closing expected Oct. 1, 2026.
  • Net proceeds estimated at about USD 3.7 billion; earmarked for capped calls, partial 2027 note repurchases, general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Snowflake Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290231BIZWIRE_USPR_____20260928_BW854921) on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations

Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.

华尔街见闻•2026/10/22 21:01